FGFR1 and diabetes mellitus: In vivo, we demonstrated that AcSDKP reversed the diabetes-suppressed FGFR1 and P-MAP4K4 levels associated with the induction of TGFβ/smad signaling and EndMT in endothelial cells in hearts and kidneys.